Precision BioSciences Moves Higher After Commencing Dosing In PBCAR269A Combination Arm Of Multiple Myeloma Trial

by Vandana Singh, Benzinga Editor

June 28, 2021 9:16 AM | 1 min read | Make a Comment

Precision BioSciences Inc DTIL and SpringWorks Therapeutics Inc SWTX have dosed the first patient in the combination arm of Precision's Phase 1/2a trial evaluating PBCAR269A.
In the study, Precision's investigational allogeneic BCMA-targeted CAR T cell therapy will be combined with nirogacestat, SpringWorks' investigational gamma-secretase inhibitor in relapsed/refractory multiple myeloma.
The Company will share interim monotherapy data for PBCAR269A later this year and conduct IND enabling studies to advance PBCAR269B, an immune-evading, stealth cell formulation, into the clinic in 2022.
Price Action: DTIL shares are up 14.6% at $13.05 during the premarket session on the last check Monday.

Posted In: Biotech News Health Care Contracts Small Cap General Briefs multiple myeloma

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.